OncLive TV

Matthew Galsky, MD, discusses the emergence of ICIs the neoadjuvant setting of bladder cancer.

Matthew Galsky, MD, discusses the standing of immune checkpoint inhibitors in bladder cancer.

Matthew Galsky, MD, disusses how the treatment paradigm of bladder cancer has shifted over time.

Gerald Soff, MD, discusses data from the phase 3 RECITE trial showing that romiplostim reduces chemotherapy dose modifications in patients with GI cancer.

Jennifer Eads, MD, discusses data for the CAR T-cell therapy CHM-2101 in relapsed/refractory GI cancers.

John Mascarenhas, MD, discusses key data from the SENTRY trial of selinexor plus ruxolitinib in JAK inhibitor–naïve myelofibrosis.

Tycel Phillips, MD, discusses the FDA approval of sonrotoclax in mantle cell lymphoma and where the agent can be best applied in the treatment paradigm.

Linda R. Mileshkin, MBBS, FRACP, Mbioeth, highlights efficacy data with puxitatug samrotecan in patients with ovarian and endometrial cancers.

Tony Mok, BMSc, MD, FRCPC, FHKCP, FHKAM, FRCP, notes the implications of 7-year data from the CROWN study of frontline lorlatinib in ALK-positive NSCLC.

Daniel King, MD, PhD, discusses the implications of the RASolute 302 study of daraxonrasib in previously treated metastatic pancreatic adenocarcinoma.

Joyce Nuqui Barlin, MD, shares the rationale for studying gotistobart plus pembrolizumab in patients with pretreated platinum-resistant ovarian cancer.

Alan L. Ho, MD, PhD, discusses next steps for the evaluation of Oz-V in OPSCC based on its phase 2 efficacy in patients with treatment-refractory disease.

Lucy Gilbert, MD, discusses overall survival data with relacorilant plus nab-paclitaxel based on prior taxane use from the phase 3 ROSELLA trial in platinum-resistant ovarian cancer.

Coral Olazagasti, MD, discusses the significance of providing resources to oncology physicians who are looking to strengthen their overall wellness.

Kelly Elizabeth McCann, MD, PhD, discusses the need for breast cancer research that encompasses drugs with different payloads.

Kelly Elizabeth McCann, MD, PhD, discusses the TROP2-directed ADCs that are clinically available for metastatic TNBC management.

Kelly Elizabeth McCann, MD, PhD, discusses considerations for the sequential use of ADCs with similar payloads in HER2-positive metastatic breast cancer.

Kelly Elizabeth McCann, MD, PhD, discusses the role of post-neoadjuvant T-DXd in HER2-positive breast cancer.

Marwan G. Fakih, MD, discusses the synergy between liquid and tissue biopsies and the need for a data-driven approach to repeat ctDNA testing in CRC.

Alan L. Ho, MD, PhD, discusses safety data from a phase 2 trial of ozuriftamab vedotin in HPV-associated OPSCC.

Alan L. Ho, MD, PhD, discusses safety data from a phase 2 trial of ozuriftamab vedotin in HPV-associated OPSCC.

Marwan G. Fakih, MD, discusses the pitfalls of using liquid TMB for immunotherapy selection and the need for tissue-liquid biopsy concordance in CRC.

Ginger J. Gardner, MD, FACOG, discusses the importance of elevating the national conversation surrounding gynecologic cancers through collaborative efforts.

Kelly Elizabeth McCann, MD, PhD, discusses the clinical utility of T-DXd followed by THP for HER2-positive early breast cancer.

Ajai Chari, MD, discusses treatment navigation in relapsed/refractory multiple myeloma in the era of CAR T-cell therapies and bispecific antibodies.

Alex Herrera, MD, discusses safety data and considerations for nivolumab plus AVD in classical hodgkin lymphoma.

Lyudmila A. Bazhenova, MD, discusses the evolving treatment landscape in ROS1-rearranged metastatic NSCLC.

Tanios S. Bekaii-Saab, MD, FACP, discusses how the REDMOD AI model could help identify prediagnostic pancreatic cancer on CT scans missed by radiologists.

Rena D. Callahan, MD, discusses the clinical implications of the FDA approval of Dato-DXd for the treatment of patients with unresectable/metastatic TNBC.

Stefan K. Barta, MD, MS, discusses how to distinguish MAR from mycosis fungoides lesions in cutaneous T-cell lymphoma.